1/9
Vocabulary flashcards covering ethical guidelines, codes, and scenario analyses for clinical research based on the Nuremberg Code, the Belmont Report, and the Declaration of Helsinki.
Declaration of Helsinki
A set of ethical guidelines for clinical trials issued by the World Medical Association in 1964
Nuremberg Code
Voluntary consent, minimize harm, scientific value, and the right to withdraw
Belmont Report
Risk and benefit ratios are carefully evaluated to ensure trials present higher benefits than probable risks, while protecting subject autonomy and vulnerable populations from exploitation.
Placebo Use (Ethical Criteria)
ā¢Ā Use of placebo will have an impact on the patientās interest and right to receive the best proven care. (Helsinki)
⢠It could be life-threatening for life-threatening events (stroke / cardiac arrest) if patient donāt receive treatment immediatelyĀ
⢠ Experimental investigation should always be compared against the best methods, and placebo should only be used if there is no proven standard of care to be used as a references or
⢠Can be used on top of a standard care (as a comparator drug; patient still receiving some drugs, not totally off medication)
⢠Use of placebo use must be have scientific justification, not just for convenience.
Disease Induction Criteria
ā¢Ā The disease under study is mild and reversible,
ā¢Ā The risk is minimal and scientifically justified,
ā¢Ā Participants are fully informed and voluntarily consent.
Undue Influence
Coercively claiming a trial is a terminally ill patient's last hope of survival
Threatens patient into joining the trial, without giving them the rights to exercise free power of choice. (Nuremberg Code / Belmont Report)
Undermines voluntary informed consent. Consent should be carried out without any coercion and threat.
Subjectās autonomy is compromised as he preys on fear and desperation, especially in a terminally ill or emotionally vulnerable subject.
Vulnerable Subjects
Participant populations with diminished autonomy or compromised decision-making capacity (such as dementia patients, dying patients, or prisoners on death row) who require special protection against exploitation, pressure, and undue influence.
Legally Authorised Representative (LAR)
A surrogate decision-maker legally permitted to provide consent on behalf of a vulnerable patient, acting strictly in the subject's best interest.
Conditions for Research on Dementia Patients
Ā
Ā
⢠Patient is dementia = vulnerable subjects = unable to comprehend the information provided; thus unable make decision for herself & to voluntary give valid consent during the informed consent process.Ā
⢠Under GCP, IC process involved voluntary participation after being informed of all aspect of the trial that will influence the patientās decision.
⢠Patient can only be included provide there is a legally authorised representative (LAR) to give consent acting in the subjectās best interest. But patientās assent should still be obtained at all possible
⢠There is a need to consult the patientās physician that it is beneficial for the patient to participate in the trial, ensure the best interest of the subject.Ā
⢠Dementia patient should not be included in the trial if it could be done on a non-vulnerable patient.
⢠They can only be involved if the trial is related to their condition.
Risk and Benefit Ratio
An ethical evaluation under the Belmont Report ensuring benefits outweigh risks.
Research must avoid subjecting patients to unnecessary harm and,
must not be conducted if expected adverse effects involve disabling injury or multiple organ damage without justification.